Clinical & experimental ophthalmology · 2007
Bilateral angle closure glaucoma induced by sulphonamide-derived medications.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Grace C, Tam Christina P, Danesh-Meyer Helen V, Myers Jonathan S, Katz L Jay
Аннотация
BACKGROUND: Sulphonamide-derived medications are widely used, although not always recognized as such. We report the occurrence of bilateral angle closure glaucoma with sulphonamide-derived medications and highlight features of the presentation and treatment to assist in early diagnosis and management.
METHODS: The clinical records of three cases with bilateral angle closure glaucoma induced by three sulphonamide-derived medications, sulfasalazine, oral acetazolamide, and hydrochlorothiazide, were reviewed.
RESULTS: All three cases identified presented with bilateral angle closure glaucoma and persistent elevated intraocular pressure despite patent iridotomy. Patients may be pseudophakic (2) or phakic (1). Cessation of the suspected medication is necessary to reverse the mechanism.
CONCLUSIONS: The proposed mechanism of angle closure glaucoma induced by sulphonamide medication involves an idiosyncratic reaction in the uveal tissues to these systemic drugs that is associated with expansion of the extracellular tissue of the ciliary body and choroid. Management identification of sulphonamide-derived medications and immediate cessation of suspected sulphonamide-derived medication, refraction and ultrasound B scan or ultrasound biomicroscopy may aid in the proper diagnosis and can also be helpful for confirmation.
METHODS: The clinical records of three cases with bilateral angle closure glaucoma induced by three sulphonamide-derived medications, sulfasalazine, oral acetazolamide, and hydrochlorothiazide, were reviewed.
RESULTS: All three cases identified presented with bilateral angle closure glaucoma and persistent elevated intraocular pressure despite patent iridotomy. Patients may be pseudophakic (2) or phakic (1). Cessation of the suspected medication is necessary to reverse the mechanism.
CONCLUSIONS: The proposed mechanism of angle closure glaucoma induced by sulphonamide medication involves an idiosyncratic reaction in the uveal tissues to these systemic drugs that is associated with expansion of the extracellular tissue of the ciliary body and choroid. Management identification of sulphonamide-derived medications and immediate cessation of suspected sulphonamide-derived medication, refraction and ultrasound B scan or ultrasound biomicroscopy may aid in the proper diagnosis and can also be helpful for confirmation.